nContact of Morrisville, NC received FDA go-ahead to market its new EPi-Sense Guided Coagulation Device for treatment of atrial fibrillation and atrial flutter. 
The device contains special sensors along the ablation section, which assist physicians in making sure the tip is properly in contact with cardiac tissue. Once ablated, the electrical signal of the region can be checked to confirm proper lesion formation. More about the device from its product page:
The EPi-Sense® further enhances the advantages of the Convergent Procedure with the utilization of EP mapping for ablation on the epicardium of the atrium and ventricle. This device is believed to be the first ablation tool designed for hybrid use by surgeons and EPs for various arrhythmia procedures. Additionally, the new embedded sensing electrodes indicate when the EPi-Sense® is in contact with cardiac tissue, which assures the heating element, in certain difficult to reach spots, is directed into the heart. EPi-Sense® has received CE Mark approval for the treatment of cardiac arrhythmias including atrial fibrillation.
Press release: FDA Clears nContact’s Cardiac Ablation Device, EPi-Sense® With Embedded Sensors
Product page: EPi-Sense
(hat tip: MassDevice)